TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11908811

Group type: EXPERIMENTAL
Intervention: Immunostimulants
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30701377

Group type: EXPERIMENTAL
Intervention: Extended self-management tools intervention
Number of subjects: 181

Group type: COMPARATOR
Intervention: Brief Check Your Gambling intervention
Number of subjects: 181
Study: 29508635

Group type: EXPERIMENTAL
Intervention: Levothyroxine/liothyronine combination therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Levothyroxine alone
Number of subjects: 39
Study: 26784863

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 327

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 327
Study: 24184641

Group type: EXPERIMENTAL
Intervention: Continuous microwave diathermy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Pulsed microwaves
Number of subjects: 149

Group type: COMPARATOR
Intervention: Unplugged microwaves (Control)
Number of subjects: 149
Study: 22305534

Group type: EXPERIMENTAL
Intervention: Formula enriched with milk fat globule membrane (INPULSE), 200 mL daily for 4 months
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Formula enriched with milk fat globule membrane (INPULSE)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control formula (without milk fat globule membrane)
Number of subjects: 182
Study: 20920265

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 565)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Control group (n = 561)
Number of subjects: 1126
Study: 17635246

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 41
Study: 15618073

Group type: EXPERIMENTAL
Intervention: Dual chamber pacemaker with antitachyarrhythmia-pacing capability
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Device-gathered diagnostic measures
Number of subjects: 105

Group type: COMPARATOR
Intervention: Crossover design
Number of subjects: 105

Group type: COMPARATOR
Intervention: Parallel design
Number of subjects: 105

Group type: COMPARATOR
Intervention: Doubling the study period
Number of subjects: 105
Study: 11999236

Group type: COMPARATOR
Intervention: VIC-I (1996-1998)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: VIC-II (1999-2000)
Number of subjects: 460
Study: 10623333

Group type: EXPERIMENTAL
Intervention: NebuChamber spacer (AstraZeneca, Lund, Sweden)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Babyhaler spacer (GlaxoWellcome, Hertfordshire, UK)
Number of subjects: 13
Study: 7869208

Group type: EXPERIMENTAL
Intervention: Ca gluconate-glycerophosphate preparation (group CaGP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ca phosphate (group CaTB)
Number of subjects: 26
Study: 2374358

Group type: EXPERIMENTAL
Intervention: Intensive macrofractional irradiation (25 Gr cumulative local dose)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy and surgery with local UHF hyperthermia)
Number of subjects: 451
Study: 204971

Group type: EXPERIMENTAL
Intervention: INH 5 mg/kg body weight + RMP 10 mg/kg body weight + EMB 25 mg/kg body weight daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: INH 15 mg/kg body weight + RMP 10 mg/kg body weight + EMB 40 mg/kg body weight, intermittent administration (2/7)
Number of subjects: 75
Study: 31084557

Group type: EXPERIMENTAL
Intervention: Clearfil Tri-S Bond Plus with Clearfil Majesty ES-2 composite (TS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single Bond Universal in self-etch mode with Filtek Z350 XT composite (SB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Plafique Bond with Plafique LX 5 composite (PB)
Number of subjects: 24
Study: 28458128

Group type: EXPERIMENTAL
Intervention: Presence of safety signals during extinction
Number of subjects: 48

Group type: COMPARATOR
Intervention: Absence of safety signals during extinction
Number of subjects: 48
Study: 24696226

Group type: EXPERIMENTAL
Intervention: Intensive motivational adherence counselling
Number of subjects: 297

Group type: COMPARATOR
Intervention: Didactic counselling
Number of subjects: 297
Study: 25122429

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 1967
Study: 22932864

Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Subdural drain (SDD)
Number of subjects: 50
Study: 19131370

Group type: EXPERIMENTAL
Intervention: Cilostazol 100mg twice a day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17126073

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15314537

Group type: EXPERIMENTAL
Intervention: Robot-aided progressive resistance training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Active-assisted robot-aided exercises
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Robot-aided exercise training (all groups)
Number of subjects: 46
Study: 15131468

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 11318908

Group type: EXPERIMENTAL
Intervention: Intervention (quEST intervention)
Number of subjects: 479
Study: 9129604

Group type: EXPERIMENTAL
Intervention: 1 min treadmill exercise test
Number of subjects: 24

Group type: COMPARATOR
Intervention: Heel raising exercise
Number of subjects: 24
Study: 7961258

Group type: EXPERIMENTAL
Intervention: Energy intake increased by 50% with no change in physical activity (positive energy balance)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TEE increased by 50% by increasing physical activity, matched by a 50% increase in energy intake (energy balance at high energy flux)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TEE increased by 50% by increasing physical activity with no change in energy intake (negative energy balance)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No change in energy intake or physical activity (energy balance at low energy flux)
Number of subjects: 19
Study: 3599226

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 150 mg netilmicin sulfate 1 hour preoperatively
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular injection of 1.5 ml of 0.9% sodium chloride 1 hour preoperatively
Number of subjects: 100
Study: 31920016

Group type: EXPERIMENTAL
Intervention: Oral zabofloxacin for the treatment of COPD exacerbations
Number of subjects: 0
Study: 30497488

Group type: EXPERIMENTAL
Intervention: Ojeok-san
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28494802

Group type: EXPERIMENTAL
Intervention: Active intervention (smartphone app with psychoeducational materials and exercises based on CBT for depression)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo intervention (sham version of the app with similar structure of courses and exercises)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Delayed intervention (access to the app after 6 weeks)
Number of subjects: 220
Study: 26150070

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (24IU)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23064993

Group type: EXPERIMENTAL
Intervention: Hip Arthroscopy (HA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Surgical Hip Dislocation (SHD)
Number of subjects: 38
Study: 21592309

Group type: EXPERIMENTAL
Intervention: Oral morphine (30 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18720130

Group type: EXPERIMENTAL
Intervention: Eccentric training for tendinopathy of the AT
Number of subjects: 116
Study: 16689000

Group type: EXPERIMENTAL
Intervention: Salpingostomy combined with Bushen Huoxue Decoction (BHD), 1 dose every day starting from the 5th day of menstrual cycle for 14 days, with hydrotubation using Xiangdan Injection (XI) applied once in the next menstrual cycle after salpingostomy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salpingostomy alone with hydrotubation using Xiangdan Injection (XI).
Number of subjects: 0
Study: 12712779

Group type: EXPERIMENTAL
Intervention: Midazolam and fentanyl (Group MF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol and fentanyl (Group PF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam and remifentanil (Group MR)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (Group PR)
Number of subjects: 80

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 80
Study: 11178293

Group type: EXPERIMENTAL
Intervention: Minimally invasive LIMA-to-LAD bypass
Number of subjects: 158
Study: 8708654

Group type: EXPERIMENTAL
Intervention: Aspirin low dose (< 100 mg per day)
Number of subjects: 6171

Group type: EXPERIMENTAL
Intervention: Aspirin medium dose (300 to 325 mg per day)
Number of subjects: 6171

Group type: EXPERIMENTAL
Intervention: Aspirin high dose (> 900 mg per day)
Number of subjects: 6171

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 6171
Study: 1424410

Group type: EXPERIMENTAL
Intervention: 200 mg toloxatone three times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg toloxatone three times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3936106

Group type: EXPERIMENTAL
Intervention: Baclofen (30‐90 mg per day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30291012

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) arm (<120mmHg)
Number of subjects: 978

Group type: COMPARATOR
Intervention: Standard arm (SBP<140mmHg)
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 978
Study: 27718248

Group type: EXPERIMENTAL
Intervention: Active CWMT
Number of subjects: 148

Group type: COMPARATOR
Intervention: Nonadaptive/placebo version of CWMT
Number of subjects: 148

Group type: COMPARATOR
Intervention: No training
Number of subjects: 148
Study: 25398971

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH) plus recombinant LH (rLH)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Highly purified hMG (HP-hMG)
Number of subjects: 579
Study: 24414382

Group type: EXPERIMENTAL
Intervention: Wrist position at 45°
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wrist position at 0°
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wrist position at 15°
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wrist position at 30°
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wrist position at 60°
Number of subjects: 100
Study: 21920062

Group type: EXPERIMENTAL
Intervention: High-soya diet for 6 months
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Low-soya diet for 6 months
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High-soya diet
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Low-soya diet
Number of subjects: 79

Group type: COMPARATOR
Intervention: Comparison between high-soya and low-soya diets
Number of subjects: 79
Study: 19530004

Group type: EXPERIMENTAL
Intervention: Intermittent fetal pulse oximetry (FPO) plus fetal heart rate (FHR) monitoring
Number of subjects: 230

Group type: COMPARATOR
Intervention: FHR monitoring alone (Control)
Number of subjects: 230
Study: 18158708

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no ACE inhibitor)
Number of subjects: 16
Study: 15122049

Group type: EXPERIMENTAL
Intervention: Typbar
Number of subjects: 184

Group type: COMPARATOR
Intervention: Vaccine 'X'
Number of subjects: 184
Study: 11808977

Group type: EXPERIMENTAL
Intervention: Urinary iPF2alpha‐III concentrations in patients with Crohn's disease
Number of subjects: 23

Group type: COMPARATOR
Intervention: Urinary iPF2alpha‐III concentrations in healthy controls
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Urinary iPF2alpha‐III concentrations in patients with clinical relapse
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Urinary iPF2alpha‐III concentrations in patients with clinical remission
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Correlation between urinary iPF2alpha‐III and plasma C-reactive protein concentrations
Number of subjects: 23
Study: 10024259

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg or 20 mg daily for 2 weeks
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 2 weeks
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Intermittent treatment overall
Number of subjects: 677
Study: 7580003

Group type: EXPERIMENTAL
Intervention: Depot leuprorelin (3.75 mg IM injection)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Daily buserelin (0.3 mg SC twice daily)
Number of subjects: 117
Study: 2134562

Group type: EXPERIMENTAL
Intervention: Cimetidine intermittent infusion (300 mg every 8 hours)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cimetidine intermittent infusion (300 mg every 6 hours)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cimetidine continuous infusion (600 mg per day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cimetidine continuous infusion (900 mg per day)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cimetidine continuous infusion (1200 mg per day)
Number of subjects: 27
Study: 6159711

Group type: EXPERIMENTAL
Intervention: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 2 months followed by thiacetazone plus isoniazid for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 2 months followed by thiacetazone plus isoniazid for 8 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 1 month followed by thiacetazone plus isoniazid for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 1 month followed by twice-weekly streptomycin, isoniazid and pyrazinamide for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-drug regimen without pyrazinamide for 2 months followed by thiacetazone plus isoniazid for 6 months
Number of subjects: 0
Study: 6140492

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg twice a day for seven days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single 2 g dose of metronidazole after placebo failure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Recurrence of infection after treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clinical findings
Number of subjects: 40
Study: 30045174

Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging with computer simulation (n = 10)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tissue-based planning without simulation (n = 13)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall breast augmentation (both groups)
Number of subjects: 100
Study: 26219549

Group type: EXPERIMENTAL
Intervention: Face Mask (FM) therapy with a force of 400g for each side
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Skeletal Anchorage (SA) therapy with intermaxillary elastics and a force of 200g
Number of subjects: 50
Study: 24859491

Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Imipramine (150 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22313027

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (individualized counselling aimed at reducing weight and increasing physical activity)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 522
Study: 20399994

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg (steady state)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg (steady state)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg (steady state)
Number of subjects: 36
Study: 19298033

Group type: EXPERIMENTAL
Intervention: Conventional nonnavigated instrumentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional, open navigated instrumentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive navigated experimental instrumentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive navigation-dedicated instrumentation
Number of subjects: 0
Study: 15003431

Group type: EXPERIMENTAL
Intervention: Gepirone-IR
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 11285968

Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 110
Study: 9135508

Group type: EXPERIMENTAL
Intervention: Idarubicin 35 mg/m2 day 1 and prednimustine 100 mg/m2 days 2-6, every 21 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Idarubicin 15 mg/m2 days 1, 2 and 3 and prednimustine 100 mg/m2 days 2-6, every 21 days
Number of subjects: 19
Study: 7534946

Group type: EXPERIMENTAL
Intervention: Saruplase (20 mg bolus plus 60 mg continuous 1 h i.v. infusion)
Number of subjects: 12
Study: 3556262

Group type: EXPERIMENTAL
Intervention: Compound analgesic/anti-emetic formulation (paracetamol 500 mg, codeine phosphate 8 mg, buclizine hydrochloride 6.25 mg, dioctyl sodium sulphosuccinate 10 mg) taken as two tablets during acute attack
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 34
Study: 29857919

Group type: EXPERIMENTAL
Intervention: Combination therapy of rosuvastatin (5, 10, and 20 mg) with ezetimibe (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin monotherapy (5, 10, and 20 mg)
Number of subjects: 0
Study: 26709942

Group type: COMPARATOR
Intervention: PBSS (control group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modified-live virus vaccines (groups B, C, D, E)
Number of subjects: 54
Study: 24410993

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22867111

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU compounded vitamin D3 capsule monthly)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (identical inert capsule)
Number of subjects: 400
Study: 20302407

Group type: EXPERIMENTAL
Intervention: Levator resection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Levator plication
Number of subjects: 20
Study: 17574729

Group type: EXPERIMENTAL
Intervention: Tolterodine ER (2mg once daily) for 12 months
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 15591735

Group type: EXPERIMENTAL
Intervention: Birch toothpick with AmF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Birch toothpick with NaF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dental floss with AmF + NaF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dental floss without F
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control period without any approximal cleaning
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: AmF toothpick
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NaF toothpick
Number of subjects: 15
Study: 12188594

Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Structured Relapse Prevention (RP)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Random assignment to aftercare consistent with participant preference
Number of subjects: 133
Study: 9831971

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 70
Study: 8076917

Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 2692264

Group type: EXPERIMENTAL
Intervention: Metronidazole and ampicillin treatment for one to four days, wounds closed on the fourth day.
Number of subjects: 0
Study: 4936439

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 30898323

Group type: EXPERIMENTAL
Intervention: Individual female-specific cognitive behavioral therapy (I-FS-CBT)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Group female-specific cognitive behavioral therapy (G-FS-CBT)
Number of subjects: 155
Study: 28977019

Group type: EXPERIMENTAL
Intervention: Fluid chart and a cup (200ml)
Number of subjects: 138
Study: 26912161

Group type: EXPERIMENTAL
Intervention: α-linolenic acid (ALA) treatment (4.0 g daily for 12 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 26
Study: 25432827

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (ORRP)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical prostatectomy
Number of subjects: 148
Study: 22151299

Group type: EXPERIMENTAL
Intervention: Training administered to working mothers on breastfeeding techniques, duration: five home visits starting two weeks before returning to work until infants are six months old.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untrained mothers)
Number of subjects: 0
Study: 19219236

Group type: EXPERIMENTAL
Intervention: Iron-fortified rice for 16 weeks
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo rice for 16 weeks
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Total iron intake of 53.76mg from fortified rice
Number of subjects: 354
Study: 17649720

Group type: EXPERIMENTAL
Intervention: ATRA + As4S4 + chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: ATRA + chemotherapy
Number of subjects: 60
Study: 14997024

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard parenteral nutrition protocols
Number of subjects: 36
Study: 11595001

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 1385

Group type: COMPARATOR
Intervention: Tension-type headache
Number of subjects: 1385